氟比洛芬（酯）引起的肝损伤病例报告及文献评价

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (5): 291-295.

氟比洛芬（酯）引起的肝损伤病例报告及文献评价

刘浩¹,郭代红¹,宋艳东²,柴栋¹,马亮¹

1解放军总医院药学部临床药学中心，北京100853;
2天津医科大学药学院，天津300070

收稿日期:2017-12-20 修回日期:2018-06-21 出版日期:2018-05-20 发布日期:2018-06-21
作者简介:刘浩，男，本科，主管药师，临床药学。*通讯作者：郭代红，女，主任药师·硕导，临床药学与药物警戒。E-mail:guodh301@163.com

Review on Cases and Literature of Flurbiprofen (Axetil)-induced Liver Damage

LIU Hao¹ ,GUO Dai-hong¹, SONG Yan-dong² ,CHAI Dong¹ ,MA Liang¹

Center of Clinical Pharmacy, Department of Pharmacy, PLA General Hospital, Beijing 100853, China;
Tianjin Medical University, Tianjin 300070, China

Received:2017-12-20 Revised:2018-06-21 Online:2018-05-20 Published:2018-06-21

摘要/Abstract

摘要： 目的评价临床应用氟比洛芬（酯）与患者肝损伤的关联性。方法以氟比洛芬（酯）为主题词，以药品不良反应（ADR）、肝毒性、肝损伤、转氨酶及高胆红素为检索词，全面检索CNKI、万方医学数据库、VIP、Pubmed、Medline、Cochrane Central数据库，收集1980年1月至2017年11月国内外发表的文献；阅读并筛选文献，将有关ADR报道，药物安全性研究报道纳入研究；设计数据记录表，提取基本信息、方法特征、干预措施等信息；采用描述性评价方法判断氟比洛芬（酯）引起肝损伤的发生概率、程度及类型。结果根据纳入标准共筛选出8篇有效文献，3篇随机试验，1篇处方统计，1篇病例统计，3篇单个病例数据研究；分析3篇随机试验，共涉及1 210名患者，约1%的患者出现肝功能异常，初步判断氟比洛芬（酯）致肝损伤较常见；6篇文献记录了患者肝损伤的异常指标，5篇文献指出转氨酶异常，2篇文献指出碱性磷酸酶异常，均未提及胆红素指标的变化，判断该药主要引起轻度肝损伤并以转氨酶异常为主。结论笔者认为氟比洛芬（酯）致肝损伤较常见，以轻度及转氨酶异常为主。但是目前所筛文献数量有限，质量较差，后期将通过对笔者所在医院更多的临床案例进行统计分析，进一步说明氟比洛芬（酯）与患者肝损伤的关联性。

关键词: 关键字：氟比洛芬（酯）, 不良反应, 药物性肝损伤, 系统评价

Abstract: Objective To evaluate the association between flurbiprofen axetil and liver damage in clinical use.Methods Taking flurbiprofen (axetil) as subject terms, and adverse drug reactions, hepatotoxicity, hepatic damage, transaminases and hyperbilirubin as search term, the authors collected literatures from CNKI, WANFANG Medical Database, VIP Database, Pubmed, Medline and Cochrane CENTRAL Database published at home and abroad from January 1980 to November 2017. The literatures were read and screened for the ADR case reports and drug safety research reports into the study. Data record sheets was designed and the basic information, method feature and intervention were picked up and recorded. Using descriptive research method, the authors evaluated the probability, extent and type of liver damage caused by flurbiprofen (axetil).Results There were 3 randomized trials studies, 1 prescription statistic study, 1 case statistic study and 3 individual case data studies in 8 papers screened. By analyzing 1 210 patients in 3 randomized trials studies, the authors found that about 1% of patients have abnormal liver function. Then they concluded that flurbiprofen (axetil)-induced liver damage was not an uncommon adverse effect. 6 literatures recorded abnormal indicators of liver function without the changes of the bilirubin index. 5 of them indicated abnormal transaminase index and 2 of them indicated abnormal alkaline phosphatase index. The degree of liver damage is judged to be mild and abnormal transaminase to be the main type of liver injury.Conclusion The authors think that flurbiprofen (axetil)-induced liver damage is a common adverse effect and the degree of injury is mainly mild and abnormal transaminase is judged as the main type of liver injury. Considering the limited number and poor quality of current literatures, the relationship between flurbiprofen (axetil) and liver damage needs further study with more clinical statistical analysis in the authors' hospitals.

Key words: flurbiprofen (axetil), adverse reaction, drug induced liver damage(DILD), systematic review

中图分类号:

R994.11

刘浩,郭代红,宋艳东,柴栋,马亮 . 氟比洛芬（酯）引起的肝损伤病例报告及文献评价[J]. 中国药物警戒, 2018, 15(5): 291-295.

LIU Hao,GUO Dai-hong, SONG Yan-dong,CHAI Dong,MA Liang. Review on Cases and Literature of Flurbiprofen (Axetil)-induced Liver Damage[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 291-295.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/

https://zgywjj.magtechjournal.com/CN/Y2018/V15/I5/291

参考文献

[1] 徐洁, 宋玲, 陆军, 等. 氟比洛芬酯脂微球在大鼠和比格犬体内的药动学及组织分布和排泄研究[J]. 中国临床药理学与治疗学, 2015, 20(12): 1373-1377.
[2] 李健和, 胡焰, 曹俊华, 等. 非甾体抗炎药物注射制剂的开发与临床应用[J]. 中国新药与临床杂志, 2013, 32(3): 167-176.
[3] 吴燕, 李冬梅, 徐超斗, 等. 氟比洛芬酯脂微球注射液的制备及其质量评价[J]. 中国药学杂志, 2013, 48(21): 1847-1851.
[4] Mizushima Y. Lipid microspheres (lipid emulsions) as a drug carrier-An overview[M]. Advanced Drug Delivery Reviews, 1996: 113-115.
[5] 北京泰德制药股份有限公司.（凯纷）氟比洛芬酯注射液说明书[EB/OL]. [2017-12-10]. http://www.tidepharm.com/_d276214985. htm.
[6] 倪晓 , 钟晗, 刘晓琰. 氟比洛芬酯注射液致癫痫发作1例[J]. 中国药物警戒, 2012, 9(7) : 443.
[7] Ohmuka O. Lipo-NSAID preparation[J]. Advanced Drug Delivery Reviews, 1996, 20(2): 203-207.
[8] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769.
[9] Moher D, Jadad A R, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions [J]. Int J Technol Assess Health Care, 1996, 12(2): 195-208.
[10] 陈集志，李刚，徐江红，等. 住院患者应用氟比洛芬酯注射液回顾性分析[J]. 中国药师, 2012, 15(4): 542-544.
[11] Littlewood T, Hunter A, Beck P, et al. Treatment of hypercalcaemia in sarcoidosis with flurbiprofen[J]. BRITISH MEDICAL JOURNAL, 1983, 287(10): 2.
[12] Dag M S, Aydinli M, Ozturk Z A, et al. Drug- and herb-induced liver injury: A case series from a single center[J]. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2014, 25(1): 41-45.
[13] 刘风群. 氟比洛芬与双氯芬酸治疗膝关节炎的比较[J]. 国外医学·药学分册, 1991,18 (4): 245-246.
[14] 金新天, 陈文庆, 刘刚. 氟比洛芬酯脂微球注射液对老年癌痛镇痛作用的临床分析[J]. 中国实用医学, 2011, 6(8): 55-57.
[15] 西娜, 赵冠人. 氟比洛芬酯致急性肝损伤1例[J]. 解放军药学学报, 2017, 33(3): 297.
[16] 祁峰，张婷，吴玲玲. 复方骨肽注射液、氟比洛芬酯注射液致不良反应1例[J]. 中国药师, 2014, 17(7): 1202-1203.
[17] Faich G A, Castle W, Bankowski Z. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group[J]. Int J Clin Pharmacol Ther Toxicol, 1990, 28(4): 133-138.
[18] Caille G, Du Souich P, Vezina M, et al. Pharmacokinetic interaction between flurbiprofen and antacids in healthy volunteers[J]. Biopharmaceutics & Drug Disposition, 1989, 10(6): 607-615.
[19] Takada M, Fukusaki M, Terao Y, et al. Postoperative analgesic effect of preoperative intravenous flurbiprofen in arthroscopic rotator cuff repair[J]. Jounal of Anesthesic, 2009, 23(4): 500-503.
[20] Michiyoshi H, Yoshiyuki N, Hiromichi K, et al. Significance of Prostaglandin E1 Administration on Hepatic Hemodynamics during Cirrhotic Liver Resection[J]. The Japanese Society of Gastroente-rological Surgery, 1994, 27(5): 1021-1027.
[21] Padda M S, Sanchez M, Akhtar A J, et al. Drug-induced cholestasis[J]. Hepatology, 2011, 53(4): 1377-1387.
[22] Alfirevic A, Gonzalez-Galarza F, Bell C, et al. In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers[J]. Genome Med, 2012, 4(6): 51.